Literature DB >> 20126509

Genetics and genomics of melanoma.

Papia Ghosh1, Lynda Chin.   

Abstract

The rapidly increasing incidence of melanoma, coupled with its highly aggressive metastatic nature, is of urgent concern. In order to design rational therapies, it is of critical importance to identify the genetic determinants that drive melanoma formation and progression. To date, signaling cascades emanating from the EGF receptor, c-MET and other receptors are known to be altered in melanoma. Important mutations in signaling molecules, such as BRAF and N-RAS, have been identified. In this review, some of the major genetic alterations and signaling pathways involved in melanoma will be discussed. Given the great deal of genetic heterogeneity observed in melanoma, it is likely that many more genetic determinants exist. Through the use of powerful genomic technologies, it is now possible to identify these additional genetic alterations in melanoma. A critical step in this analysis will be culling bystanders from functionally important drivers, as this will highlight genetic elements that will be promising therapeutic targets. Such technologies and the important points to consider in understanding the genetics of melanoma will be reviewed.

Entities:  

Year:  2009        PMID: 20126509      PMCID: PMC2771951          DOI: 10.1586/edm.09.2

Source DB:  PubMed          Journal:  Expert Rev Dermatol        ISSN: 1746-9872


  146 in total

Review 1.  Sensorineural deafness and pigmentation genes: melanocytes and the Mitf transcriptional network.

Authors:  E R Price; D E Fisher
Journal:  Neuron       Date:  2001-04       Impact factor: 17.173

Review 2.  Guilty as charged: B-RAF is a human oncogene.

Authors:  Mathew J Garnett; Richard Marais
Journal:  Cancer Cell       Date:  2004-10       Impact factor: 31.743

3.  Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

Authors:  Vikas K Goel; Alexander J F Lazar; Carla L Warneke; Mark S Redston; Frank G Haluska
Journal:  J Invest Dermatol       Date:  2006-01       Impact factor: 8.551

4.  Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells.

Authors:  K V Bhatt; R Hu; L S Spofford; A E Aplin
Journal:  Oncogene       Date:  2006-08-21       Impact factor: 9.867

5.  The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development.

Authors:  M Sibilia; A Fleischmann; A Behrens; L Stingl; J Carroll; F M Watt; J Schlessinger; E F Wagner
Journal:  Cell       Date:  2000-07-21       Impact factor: 41.582

6.  Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array.

Authors:  Steven S Shen; Peter S Zhang; Omar Eton; Victor G Prieto
Journal:  J Cutan Pathol       Date:  2003-10       Impact factor: 1.587

7.  Lifetime risks of common cancers among retinoblastoma survivors.

Authors:  Olivia Fletcher; Douglas Easton; Kristin Anderson; Clare Gilham; Marcelle Jay; Julian Peto
Journal:  J Natl Cancer Inst       Date:  2004-03-03       Impact factor: 13.506

8.  Mutations of the BRAF gene in benign and malignant melanocytic lesions.

Authors:  Amir S Yazdi; Gabriele Palmedo; Michael J Flaig; Ursula Puchta; Andrea Reckwerth; Arno Rütten; Thomas Mentzel; Heino Hügel; Markus Hantschke; Monika-Hildegard Schmid-Wendtner; Heinz Kutzner; Christian A Sander
Journal:  J Invest Dermatol       Date:  2003-11       Impact factor: 8.551

9.  Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo.

Authors:  Norman Edward Sharpless; Karuppiah Kannan; Jin Xu; Marcus Wolfram Bosenberg; Lynda Chin
Journal:  Oncogene       Date:  2003-08-07       Impact factor: 9.867

10.  Second primary neoplasms in patients with retinoblastoma.

Authors:  G J Draper; B M Sanders; J E Kingston
Journal:  Br J Cancer       Date:  1986-05       Impact factor: 7.640

View more
  22 in total

1.  Are oncogenes sufficient to cause human cancer?

Authors:  Scott E Woodman; Gordon B Mills
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-17       Impact factor: 11.205

2.  Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma.

Authors:  Olga Shakhova; Daniel Zingg; Simon M Schaefer; Lisette Hari; Gianluca Civenni; Jacqueline Blunschi; Stéphanie Claudinot; Michal Okoniewski; Friedrich Beermann; Daniela Mihic-Probst; Holger Moch; Michael Wegner; Reinhard Dummer; Yann Barrandon; Paolo Cinelli; Lukas Sommer
Journal:  Nat Cell Biol       Date:  2012-07-08       Impact factor: 28.824

3.  TET2-Dependent Hydroxymethylome Plasticity Reduces Melanoma Initiation and Progression.

Authors:  Elise Bonvin; Enrico Radaelli; Martin Bizet; Flavie Luciani; Emilie Calonne; Pascale Putmans; David Nittner; Nitesh Kumar Singh; Sara Francesca Santagostino; Valérie Petit; Lionel Larue; Jean Christophe Marine; François Fuks
Journal:  Cancer Res       Date:  2018-12-11       Impact factor: 12.701

4.  Chromosome 10, frequently lost in human melanoma, encodes multiple tumor-suppressive functions.

Authors:  Lawrence N Kwong; Lynda Chin
Journal:  Cancer Res       Date:  2014-01-22       Impact factor: 12.701

5.  From Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis.

Authors:  Aikaterini F Giannopoulou; Athanassios D Velentzas; Athanasios K Anagnostopoulos; Adamantia Agalou; Nikos C Papandreou; Stamatia A Katarachia; Dimitra G Koumoundourou; Eumorphia G Konstantakou; Vasiliki I Pantazopoulou; Anastasios Delis; Maria T Michailidi; Dimitrios Valakos; Dimitris Chatzopoulos; Popi Syntichaki; Vassiliki A Iconomidou; Ourania E Tsitsilonis; Issidora S Papassideri; Gerassimos E Voutsinas; Polydefkis Hatzopoulos; Dimitris Thanos; Dimitris Beis; Ema Anastasiadou; George Th Tsangaris; Dimitrios J Stravopodis
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

6.  Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.

Authors:  Tamás Garay; Eszter Molnár; Éva Juhász; Viktória László; Tamás Barbai; Judit Dobos; Karin Schelch; Christine Pirker; Michael Grusch; Walter Berger; József Tímár; Balázs Hegedűs
Journal:  Pathol Oncol Res       Date:  2015-03-09       Impact factor: 3.201

7.  The Levels of H11/HspB8 DNA methylation in human melanoma tissues and xenografts are a critical molecular marker for 5-Aza-2'-deoxycytidine therapy.

Authors:  Cynthia C Smith; Baiquan Li; Juan Liu; Kie-Sok Lee; Laure Aurelian
Journal:  Cancer Invest       Date:  2011-07       Impact factor: 2.176

8.  Increased survival time of a patient with metastatic malignant melanoma following immunotherapy: A case report and literature review.

Authors:  Yong Zhang; Yongping Song; Quanli Gao
Journal:  Oncol Lett       Date:  2015-05-29       Impact factor: 2.967

9.  Thoracic metastasectomy for adoptive immunotherapy of melanoma: a single-institution experience.

Authors:  Jacob A Klapper; Jeremy L Davis; R Taylor Ripley; Franz O Smith; Dao M Nguyen; King F Kwong; Leandro Mercedes; Clinton D Kemp; Aarti Mathur; Donald E White; Mark E Dudley; John R Wunderlich; Steven A Rosenberg; David S Schrump
Journal:  J Thorac Cardiovasc Surg       Date:  2010-07-02       Impact factor: 5.209

10.  GAB2 induces tumor angiogenesis in NRAS-driven melanoma.

Authors:  Y Yang; J Wu; A Demir; M Castillo-Martin; R D Melamed; G Zhang; M Fukunaga-Kanabis; R Perez-Lorenzo; B Zheng; D N Silvers; G Brunner; S Wang; R Rabadan; C Cordon-Cardo; J T Celebi
Journal:  Oncogene       Date:  2012-08-27       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.